Matthew H Kulke, MD

Zoltan Kohn Professor, Medicine

Matthew Kulke
820 Harrison Ave

Biography

Matthew Kulke, MD, is Chief of the Section of Hematology/Oncology in the Department of Medicine at Boston Medical Center and Zoltan Kohn Professor of Medicine at Boston University School of Medicine. In addition, he serves as Co-Director of the BU-BMC Cancer Center and Co-Director off the Clinical Cancer Center at BMC.

Dr. Kulke received his undergraduate degree from Princeton University, his MD from University of California, San Francisco School of Medicine and a master’s degree in medical science from Harvard Medical School. He completed his residency at Brigham and Women’s Hospital in Internal Medicine and a fellowship in medical oncology at Dana-Farber Cancer Institute.

He subsequently founded and directed the Program in Neuroendocrine Tumors at Dana-Farber Cancer Institute and Harvard Medical School, where he served as a Professor of Medicine. A leader in the research and treatment of neuroendocrine tumors, he has received numerous awards for his accomplishments as a clinical and translational investigator and as a provider of compassionate care to patients. Kulke received the George Canellos Award for Clinical Investigation and the Ruth Brufsky Award for Pancreatic Cancer Research.

He has published over 200 peer-reviewed articles and led national and international clinical trials to identify new therapeutic and diagnostic approaches to neuroendocrine tumors.

He has served as Chair of the Neuroendocrine Tumor Task Force for the National Cancer Institute, Chair of the North American Neuroendocrine Tumor Society, and Chair of the National Comprehensive Cancer Network’s neuroendocrine tumor guideline committee.

Other Positions

  • Section Chief, Hematology & Medical Oncology, Medicine, Boston Medical Center
  • Co-Director, BU-BMC Cancer Center, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University

Education

  • University of California, San Francisco, MD
  • Harvard Medical School, MMS/MMSc
  • Princeton University, BA

Publications

  • Published on 5/28/2020

    Du C, da Silva A, Morales-Oyarvide V, Dias Costa A, Kozak MM, Dunne RF, Rubinson DA, Perez K, Masugi Y, Hamada T, Brais LK, Yuan C, Babic A, Ducar MD, Thorner AR, Aguirre A, Kulke MH, Ng K, Clancy TE, Findeis-Hosey JJ, Chang DT, Hornick JL, Fuchs CS, Ogino S, Koong AC, Hezel AF, Wolpin BM, Nowak JA. Insulin-like growth factor-1 receptor expression and disease recurrence and survival in patients with resected pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 May 28. PMID: 32467349.

    Read at: PubMed
  • Published on 3/7/2020

    Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer. 2020 Mar 07. PMID: 32146619.

    Read at: PubMed
  • Published on 3/2/2020

    Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 Mar 02. PMID: 32123969.

    Read at: PubMed
  • Published on 2/1/2020

    Rosenblum RE, Harris CK, Baeg KJ, Starr JA, Brais LK, Stashek KM, Ward SC, Katona BW, Clancy TE, Wisnivesky JP, Kulke MH, Metz DC, Kim MK, Chan JA. Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors. Pancreas. 2020 02; 49(2):249-254. PMID: 32011530.

    Read at: PubMed
  • Published on 1/30/2020

    Jalbert JJ, Casciano R, Meng J, Brais LK, Pulgar SJ, Berthon A, Dinet J, Kulke MH. Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center. Oncologist. 2020 Apr; 25(4):e644-e650. PMID: 31999024.

    Read at: PubMed
  • Published on 1/8/2020

    Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2019 Nov; 30(11):1846. PMID: 31987097.

    Read at: PubMed
  • Published on 12/1/2019

    Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database. J Gastrointest Cancer. 2019 Dec; 50(4):816-823. PMID: 30121904.

    Read at: PubMed
  • Published on 11/1/2019

    Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2019 11 01; 30(11):1846. PMID: 31407000.

    Read at: PubMed
  • Published on 10/26/2019

    Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. J Patient Rep Outcomes. 2019 Oct 26; 3(1):64. PMID: 31655936.

    Read at: PubMed
  • Published on 10/1/2019

    Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019 Oct; 25(10):1627. PMID: 31501535.

    Read at: PubMed

View 198 more publications: View full profile at BUMC

View all profiles